Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded,52-week,randomized controlled study

Abstract

Background:

The long-term effects of dose reduction of atypical antipsychotics on cognitive function and symptomatology in stable patients with schizophrenia remain unclear. We sought to determine the change in cognitive function and symptomatology after reducing risperidone or olanzapine dosage in stable schizophrenic patients.

Methods:

Seventy-five stabilized schizophrenic patients prescribed risperidone (≥4 mg/day) or olanzapine (≥10 mg/day) were randomly divided into a dose-reduction group (n=37) and a maintenance group (n=38). For the dose-reduction group, the dose of antipsychotics was reduced by 50%; for the maintenance group, the dose remained unchanged throughout the whole study. The Positive and Negative Syndrome Scale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery were measured at baseline, 12, 28, and 52 weeks. Linear mixed models were performed to compare the Positive and Negative Syndrome Scale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects and MATRICS Consensus Cognitive Battery scores between groups.

Results:

The linear mixed model showed significant time by group interactions on the Positive and Negative Syndrome Scale negative symptoms, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, speed of processing, attention/vigilance, working memory and total score of MATRICS Consensus Cognitive Battery (all p<0.05). Post hoc analyses showed significant improvement in Positive and Negative Syndrome Scale negative subscale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, speed of processing, working memory and total score of MATRICS Consensus Cognitive Battery for the dose reduction group compared with those for the maintenance group (all p<0.05).

Conclusions:

This study indicated that a risperidone or olanzapine dose reduction of 50% may not lead to more severe symptomatology but can improve speed of processing, working memory and negative symptoms in patients with stabilized schizophrenia.

Keywords

Cognitive function symptomatology dose reduction antipsychotics schizophrenia

Get full access to this article

View all access options for this article.

References

Alphs

Summerfelt

Lann

et al . (1989) The negative symptom assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 25: 159–163.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington, DC: American Psychiatric Association.

Chinese Medical Association (2015) Guideline for the Prevention and Treatment of Schizophrenia in China, 2nd edn. Beijing: Chinese Medical Association.

Baldessarini

Viguera

Faedda

et al . (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52: 200–202.

Barnes

(2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25: 567–620.

Bottiggi

Salazar

et al . (2006) Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 14: 980–984.

Burton

(2006) Symptom domains of schizophrenia: The role of atypical antipsychotic agents. J Psychopharmacol 20(Suppl 6): 6–19.

David

Taylor

Kinon

et al . (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: 1085–1096.

Dixon

Dickerson

Bellack

et al . (2010) The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 36: 48–70.

10.

Elie

Poirier

Chianetta

et al . (2010) Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 24: 1037–1044.

11.

Gargoloff

O’Halloran

Boland

et al . (2003) Change in clinical status and side effects of patients treated with either olanzapine or risperidone: Six-month results from the three-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study. Schizophr Res 60: 283–284.

12.

Green

Marder

Glynn

et al . (2002) The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biol Psychiatry 51: 972–978.

13.

Andreasen

Ziebell

et al . (2011) Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68: 128–137.

14.

Kane

Leucht

Carpenter

et al . (2003) Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry 64: 1–100.

15.

Kawai

Yamakawa

Baba

et al . (2006) High-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 30: 1009–1014.

16.

Kay

Fiszbein

Opler

(1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.

17.

Knowles

David

Reichenberg

(2010) Processing speed deficits in schizophrenia: Reexamining the evidence. Am J Psychiatry 167: 828–835.

18.

Kopelowicz

Zarate

Tripodis

et al . (2000) Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 157: 987–993.

19.

Krueger

Tian

(2004) A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points. Biol Res Nurs 6: 151–157.

20.

Lane

Chang

Chiu

et al . (2001) A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. J Clin Psychiatry 62: 994–995.

21.

Lane

Chiu

Chou

et al . (2000) Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels. J Clin Psychiatry 61: 209–214.

22.

Lehman

Kreyenbuhl

Buchanan

et al . (2010) The schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull 36: 94.

23.

Lehman

Lieberman

Dixon

et al . (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(Suppl 2): 1–56.

24.

Xiang

et al . (2015) Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. Aust N Z J Psychiatry 49: 129–136.

25.

McGlashan

Zipursky

Perkins

et al . (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163: 790–799.

26.

Minzenberg

Poole

Benton

et al . (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 161: 116–124.

27.

Mizuno

Bies

Remington

et al . (2012) Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry 37: 182–187.

28.

Nagaendran

Chen

Chong

et al . (2011) Ministry of health clinical practice guidelines: Dementia. Singapore Med J 52: 293–298.

29.

Nuechterlein

Barch

Gold

et al . (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72: 29–39.

30.

Nuechterlein

Green

Kern

et al . (2008) The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 165: 203–213.

31.

Peralta

Cuesta

Martinezlarrea

et al . (2000) Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 157: 1461–1466.

32.

Procyshyn

DRM

Thompson

Tse

(2000) Pharmacoeconomics of clozapine, risperidone and olanzapine. CNS Drugs 13: 47–76.

33.

Remington

Mamo

Labelle

et al . (2006) A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 163: 396–401.

34.

Robinson

Schooler

John

et al . (2015) Medication prescription practices for the treatment of first episode schizophrenia-spectrum disorders: Data from the national RAISE-ETP study. Am J Psychiatry 172: 237–248.

35.

Rouillon

Chartier

Gasquet

(2008) Strategies of treatment with olanzapine in schizophrenic patients during stable phase: Results of a pilot study. Eur Neuropsychopharmacol 18: 646–652.

36.

Sakurai

Bies

Stroup

et al . (2013) Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. Schizophr Bull 39: 564–574.

37.

Sim

Fujii

et al . (2009) High-dose antipsychotic use in schizophrenia: A comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 67: 110–117.

38.

Simpson

Angus

(1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11–19.

39.

Suzuki

Uchida

Tanaka

et al . (2003) Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: An open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol 18: 323–329.

40.

Takeuchi

Suzuki

Remington

et al . (2013) Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: An open-label, randomized, controlled, pilot study. Schizophr Bull 39: 993–998.

41.

Torniainen

Mittendorferrutz

Tanskanen

et al . (2014) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41: 656.

42.

Uchida

Rajji

Mulsant

et al . (2009) D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol 29: 571–575.

43.

Uchida

Suzuki

Takeuchi

et al . (2011a) Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: Meta-analysis. Schizophr Bull 37: 788–799.

44.

Uchida

Takeuchi

Graffguerrero

et al . (2011b) Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol 31: 497–502.

45.

Wunderink

Nieboer

Wiersma

et al . (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70: 913–920.

46.

Yoshimura

Takeda

Kishi

et al . (2017) Optimal dosing of risperidone and olanzapine in the maintenance treatment for patients with schizophrenia and related psychotic disorders: A retrospective multicenter study. J Clin Psychopharmacol 37: 296–301.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.28 MB